Codexis, Inc.
A maker of custom-engineered enzymes, Codexis grows proteins in the lab to speed up drug-making and other industrial processes, with uses ranging from pharmaceuticals (including a key ingredient in the cholesterol drug Lipitor) to food and RNA therapies. Born in 2002 as a spin-off from biotech firm Maxygen, the company built its craft on "directed evolution" — mimicking natural selection in a dish to breed better enzymes through its CodeEvolver platform. Its name blends "code" and "exis" (evolution), a nod to the very process that powers it.
Bought 5.26M · Sold 2.66M
Granted 282.2K · Bought 58.5K
Granted 192.0K · Sold 10.1K
Granted 30.1K · Sold 20.0K
Granted 71.1K
Granted 79.2K · Bought 9.0K
Granted 52.4K · Bought 11.7K
Granted 71.1K
Granted 71.1K · Sold 9.0K
Granted 71.1K
Granted 52.4K · Bought 11.8K
Sold 13.0K
Granted 71.1K
Granted 112.2K
Granted 85.1K
Granted 88.8K · Sold 4.0K
Granted 76.9K · Sold 10.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Opaleye Management Inc.10% owner · 59 transactions | — | 10.13M | — | 5.26M | 2.66M |
| Dilly Stephen GeorgeDirector · 4 transactions | +91.1% | 727.1K | 282.2K | 58.5K | — |
| Moore AlisonPresident and CEO, Director · 6 transactions | +265.3% | 250.5K | 192.0K | — | 10.1K |
| Dorgan Byron LDirector · 2 transactions | +4.7% | 223.6Kas of Jun 2024 | 30.1K | — | 20.0K |
| Smith David VDirector · 2 transactions | +57.7% | 194.3Kas of Jun 2025 | 71.1K | — | — |
| Norrett KevinChief Operating Officer · 3 transactions | +99% | 177.3Kas of Feb 2025 | 79.2K | 9.0K | — |
| Ryali SriramChief Financial Officer · 2 transactions | +57.2% | 175.8Kas of Jan 2024 | 52.4K | 11.7K | — |
| Parker H StewartDirector · 2 transactions | +98.1% | 143.6Kas of Jun 2025 | 71.1K | — | — |
| Wolf Dennis PDirector · 3 transactions | +80.9% | 139.0K | 71.1K | — | 9.0K |
| Singhvi RahulDirector · 2 transactions | +107.8% | 137.1Kas of Jun 2025 | 71.1K | — | — |
| Fitzgerald Margaret NellSee Remarks · 2 transactions | +92.2% | 133.8Kas of Jan 2024 | 52.4K | 11.8K | — |
| Lutz StefanChief Scientific Officer · 3 transactions | — | 130.4K | — | — | 13.0K |
| Martinborough EstherDirector · 2 transactions | +122.7% | 129.0Kas of Jun 2025 | 71.1K | — | — |
| Collins CynthiaDirector · 2 transactions | — | 112.2Kas of Jun 2025 | 112.2K | — | — |
| Richards ChristosDirector · 2 transactions | — | 85.1Kas of Jun 2025 | 85.1K | — | — |
| De Vre RaymondDirector · 4 transactions | — | 84.8K | 88.8K | — | 4.0K |
| Erbez GeorgiaSee Remarks · 4 transactions | — | 66.8K | 76.9K | — | 10.1K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +2.63M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.